Bringing the Oncology Community Together

FDA Takes Aggressive Steps to Reduce Drug Shortages

The FDA announced plans to strengthen the supply of 2 scarce cancer drugs: methotrexate and Doxil.

Radiation Therapy After Surgery Shows No Survival Benefit for Elderly Lung Cancer Patients

Many older patients with stage III lung cancer who received radiation therapy fared no better than those who did not receive radiation therapy.

FDA Updates: Pertuzumab Moves Forward, Denosumab Receives Setback

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

Expanded Use of Gleevec Approved in Patients With GIST

The FDA granted regular approval for imatinib for treating patients after the surgical removal of KIT-positive GISTs.

Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients

The FDA has approved vismodegib for the treatment of patients with basal cell carcinoma.

FDA Approves Axitinib for Advanced Kidney Cancer Patients

The FDA approved axitinib for the treatment of patients with advanced RCC who have failed to respond to another drug.

Oral HPV Infections More Prevalent in Men

Approximately 7% of Americans carry the human papillomavirus (HPV) in their oral cavities, and men are 3 times more likely to carry the virus than women.

BRCA1 and BRCA2 Mutations Yield Better Prognosis in Ovarian Cancer Patients

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

FDA Approves Genzyme's Fabrazyme Plant

Genzyme Corporation announced that the FDA has approved its new manufacturing plant in Framingham, Massachusetts.

Bortezomib Approved for Subcutaneous Injection

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.

Researchers Discover Basis for Secondary Skin Cancers in Patients Taking Vemurafenib

The molecular basis behind the relatively high incidence of secondary skin cancers after patients received vemurafenib has been discovered.

HER2-Positive Patients Benefit From Combination Therapy of Trastuzumab and Lapatinib

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.

FDA Issues New Safety Warnings on Brentuximab, Including Risk of Rare Brain Infection

The FDA and Seattle Genetics announced that new warning labels would be issued for brentuximab vedotin.

DNA Analysis Finds First Gene Implicated in Prostate Cancer

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Tivozanib Demonstrates Better PFS Than Sorafenib, but Failed to Meet Investors Expectations

The investigational drug, tivozanib, showed improved rates of PFS in patients with advanced RCC than the already-approved sorafenib.

External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest

OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives

About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions